System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Publications

Clinical Trial Journal Article Epublish 2 citations

PubMed: 40495170 DOI: 10.1186/s12958-025-01424-w

Clinical outcome using the Q300™ device in a reproductive laboratory environment: an open-label, non-controlled and non-randomized study.

Reprod Biol Endocrinol 23(1):90

Authors: Yulia Michailov, Eden Amsalem, Natalia Umanski, Valeria Tamadaev, Shevach Friedler, Bozhena Saar-Ryss

Affiliations

  • Ben Gurion University of the Negev, Faculty of Health Sciences, Beer Sheva, Israel.
  • IVF Unit-Obstetrics and Gynecology Department, Barzilai Medical Center, Ashkelon, Israel.
  • IVF Unit-Obstetrics and Gynecology Department, Barzilai Medical Center, Ashkelon, Israel.
  • Ben Gurion University of the Negev, Faculty of Health Sciences, Beer Sheva, Israel.

Abstract

BACKGROUND

Infertility affects a significant portion of the global population, with male factor infertility contributing to nearly half of all cases. The success of assisted reproductive technologies (ART), such as in vitro fertilization (IVF), depends on selecting high-quality sperm with optimal motility, morphology, and DNA integrity. The Q300™ device offers a novel approach for improving sperm selection. Utilizing an advanced optical imaging system, the Q300™ isolates the morphologically compliant sperm cells sperm for injection into the oocytes. This study aims to assess the usability and preliminary clinical outcome of the Q300™ device under "real-life conditions" in a fertility laboratory setting.

METHODS

Preliminary clinical data collected from Barzilai Medical Center with or without using the technology were compared to the Key Performance Indicators (KPI) for ART laboratories according to the Vienna Consensus.

RESULTS

The data suggest that the Q300™ significantly improved day-3 embryo development, blastulation, and cumulative pregnancy rates.

CONCLUSIONS

By offering a more refined and efficient selection process, the Q300™ has the potential to redefine clinical practice in infertility treatment, providing patients with a higher likelihood of achieving successful outcomes.

TRIAL REGISTRATION

NCT06232720. Date of registration: 15 February 2023. Enrollment of first subject: 20 August 2023. For more information, visit: https://clinicaltrials.gov/study/NCT06232720 .

MeSH

Reproduction, Fertility, Laboratories, Infertility, Environment, Spermatozoa